Café

LBRX

40.9004.87%( +1.900 )

LongbridgeAI

LBRX

40.9004.87%( +1.900 )

LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia.

benzinga_article

Jul 22, 2026 at 12:55 PM

LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia.

Source: benzinga_article The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

LB Pharmaceuticals

LBRX.US

Open

High

Low

Prev Close

P/E^TTM

Market Cap

LongbridgeAI

LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia.

benzinga_article

Jul 22, 2026 at 12:55 PM

LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia.

Source: benzinga_article The copyright of this article belongs to the original author/organization.

LB Pharmaceuticals

LBRX.US

Open

High

Low

Prev Close

P/E^TTM

Market Cap